AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Tsinghua Science and Technology Article
PDF (6.8 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Open Access

Identification of Key Genes as Potential Drug Targets for Gastric Cancer

Center for High Performance Computing, Joint Engineering Research Center for Health Big Data Intelligent Analysis Technology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
School of Computer Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
Department of Statistics, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
Guangdong Provincial Key Laboratory for Genome Stability and Disease Prevention and Regional Immunity and Diseases, Department of Pathology, Shenzhen University, Shenzhen 518060, China

Md. Tofazzal Hossain and Md. Selim Reza contribute equally to this paper.

Show Author Information

Abstract

Gastric cancer (GC) is one of the most common cancers and ranks the third in cancer mortality all over the world. The goal of this study was to identify potential hub-genes, highlighting their functions, signaling pathways, and candidate drugs for the treatment of GC patients. We used publicly available next generation sequencing (NGS) data to identify differentially expressed (DE) genes. The top DE genes were mapped to STRING database to construct the protein-protein interaction (PPI) network and top hub genes were selected for further analysis. We found a total of 1555 DE genes with 870 upregulated and 685 downregulated genes in GC. We selected the top 400 (200 upregulated and 200 downregulated) genes to construct a PPI network and extracted the top 15 hub genes. The gene ontology (GO) term and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses of the 15 hub genes exposed some important functions and signaling pathways that were significantly associated with GC patients. The survival analysis of the hub genes disclosed that the lower expressions of the three hub genes CDH2, COL4A1, and COL5A2 were associated with better survival of GC patients. These three genes might be the candidate biomarkers for the diagnosis and treatment of GC. Then, we considered 3 key proteins (genomic biomarkers) (COL4A1, CDH2, and CO5A2) as the drug target proteins (receptors), performed their docking analysis with the 102 meta-drug agents, and found Everolimus, Docetaxel, Lanreotide, Venetoclax, Temsirolimus, and Nilotinib as the top ranked 6 candidate drugs with respect to our proposed target proteins for the treatment against GC patients. Therefore, the proposed drugs might play vital role for the treatment against GC patients.

Keywords

gastric cancerhub genescandidate genesmolecular dockingcandidate drugs

Electronic Supplementary Material

Download File(s)
649-664ESM.pdf (130.4 KB)

References

[1]
B. Freddie, F. Jacques, S. Isabelle, R. L. Siegel, L. A. Torre, and J. Ahmedin, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, 2018.
Crossref Google Scholar
[2]
M. Rugge, R. M. Genta, F. D. Mario, E. M. El-Omar, H. B. El-Serag, M. Fassan, R. H. Hunt, E. J. Kuipers, P. Malfertheiner, K. Sugano, et al., Gastric cancer as preventable disease, Clin. Gastroenterol. Hepatol., .
Crossref Google Scholar
[3]
Y. Shi, L. Qi, H. Chen, J. Zhang, Q. Guan, J. He, M. Li, Z. Guo, H. Yan, and P. Li, Identification of genes universally differentially expressed in gastric cancer, Biomed Res. Int., .
Crossref Google Scholar
[4]
E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. V. Grieken, and F. Lordick, Gastric cancer, The Lancet, .
Crossref Google Scholar
[5]
J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies, International Journal of Molecular Sciences, .
Crossref Google Scholar
[6]
A. R. Yusefi, K. B. Lankarani, P. Bastani, M. Radinmanesh, and Z. Kavosi, Risk factors for gastric cancer: A systematic review, Asian Pacific Journal of Cancer Prevention, .
Crossref Google Scholar
[7]
G. Herrera-Almario and V. E. Strong, Minimally invasive gastric surgery, Ann. Surg. Oncol., .
Crossref Google Scholar
[8]
J. Tey, Y. Y. Soon, W. Y. Koh, C. N. Leong, B. Vellayappan, K. Lim, and I. W. K. Ivan, Palliative radiotherapy for gastric cancer: A systematic review and meta-analysis, Oncotarget, .
Crossref Google Scholar
[9]
O. Zhandossov, G. Kaussova, and A. Koten, Combined treatment for gastric cancer: Immunological approach, Turkish J. Gastroenterol., .
Crossref Google Scholar
[10]
E. Niccolai, A. Taddei, D. Prisco, and A. Amedei, Gastric cancer and the epoch of immunotherapy approaches, World J. Gastroenterol., .
Crossref Google Scholar
[11]
L. Necula, L. Matei, D. Dragu, A. I. Neagu, C. Mambet, S. Nedeianu, C. Bleotu, C. C. Diaconu, and M. Chivu-Economescu, Recent advances in gastric cancer early diagnosis, World J. Gastroenterol., .
Crossref Google Scholar
[12]
A. S. Crystal, A. T. Shaw, L. V. Sequist, L. Friboulet, M. J. Niederst, E. L. Lockerman, R. L. Frias, J. F. Gainor, A. Amzallag, P. Greninger, et al., Patient-derived models of acquired resistance can identify effective drug combinations for cancer, Science, .
Crossref Google Scholar
[13]
A. A. Borisy, P. J. Elliott, N. W. Hurst, M. S. Lee, J. Lehar, E. R. Price, G. Serbedzija, G. R. Zimmermann, M. A. Foley, B. R. Stockwell, et al., Systematic discovery of multicomponent therapeutics, Proc. Natl. Acad. Sci., .
Crossref Google Scholar
[14]
B. Klinger, A. Sieber, R. Fritsche-Guenther, F. Witzel, L. Berry, D. Schumacher, Y. Yan, P. Durek, M. Merchant, R. Schafer, et al., Network quantification of EGFR signaling unveils potential for targeted combination therapy, Mol. Syst. Biol., .
Crossref Google Scholar
[15]
M. Bansal, J. Yang, C. Karan, M. P. Menden, J. C. Costello, H. Tang, G. Xiao, Y. Li, J. Allen, R. Zhong, et al., A community computational challenge to predict the activity of pairs of compounds, Nat. Biotechnol., .
Crossref Google Scholar
[16]
L. A. M. Griner, R. Guha, P. Shinn, R. M. Young, J. M. Keller, D. Liu, I. S. Goldlust, A. Yasgar, C. MaKnight, M. B. Boxer, et al., High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells, Proc. Natl. Acad. Sci., .
Crossref Google Scholar
[17]
M. L. Miller, E. J. Molinelli, J. S. Nair, T. Sheikh, R. Samy, X. Jing, Q. He, A. Korkut, A. M. Crago, S. Singer, et al., Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets, Sci. Signal., .
Crossref Google Scholar
[18]
Y. Tu, Q. Wu, J. He, J. Xu, S. Yu, Q. Wang, Y. Cheng, Q. Yang, S. Xu, and Y. Cao, Exploring the potential molecular mechanism of scutellaria baicalensis georgi in the treatment of gastric cancer based on network pharmacological analysis and molecular docking technology, Front. Pharmacol., .
Crossref Google Scholar
[19]
L. Guo, H. Shi, and L. Zhu, Siteng fang reverses multidrug resistance in gastric cancer: A network pharmacology and molecular docking study, Front. Oncol., .
Crossref Google Scholar
[20]
O. A. Kolawole, F. Olatomide A., and S. Banjo, Anti-gastric cancer activity of 1,2,3-triazolo[4,5-d]pyrimidine hybrids (1,2,3-TPH): QSAR and molecular docking approaches, Heliyon, .
Crossref Google Scholar
[21]
K. Li, Y. Du, L. Li, and D. -Q. Wei, Bioinformatics approaches for anti-cancer drug discovery, Curr. Drug Targets, vol. 21, no. 1, pp. 3–17, 2019.
Crossref Google Scholar
[22]
A. C. Kaushik, Y. J. Wang, X. Wang, and D. -Q. Wei, Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations, Brief. Bioinform., .
Crossref Google Scholar
[23]
M. Ö. Cingiz, G. Biricik, and B. Diri, The performance comparison of gene co-expression networks of breast and prostate cancer using different selection criteria, Interdiscip. Sci.: Comput. Life Sci., vol. 13, no. 3, pp. 500–510, 2021.
Crossref Google Scholar
[24]
D. Szklarczyk, A. L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic, N. T. Doncheva, J. H. Morris, P. Bork, et al., STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets, Nucleic Acids Res., .
Crossref Google Scholar
[25]
R. K. Patel and M. Jain, NGS QC toolkit: A toolkit for quality control of next generation sequencing data, PLoS One, .
Crossref Google Scholar
[26]
H. Li and R. Durbin, Fast and accurate short read alignment with burrows-wheeler transform, Bioinformatics, .
Crossref Google Scholar
[27]
Y. Liao, G. K. Smyth, and W. Shi, Featurecounts: An efficient general purpose program for assigning sequence reads to genomic features, Bioinformatics, .
Crossref Google Scholar
[28]
Z. Li, P. Hou, D. Fan, M. Dong, M. Ma, H. Li, R. Yao, B. Huang, G. Wang, P. Geng, et al., The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer, Cell Death Differ., vol. 24, no. 1, pp. 59–71, 2017.
Crossref Google Scholar
[29]
E. D. Tetzlaff, P. Cen, and J. A. Ajani, Emerging drugs in the treatment of advanced gastric cancer, Expert Opinion on Emerging Drugs, .
Crossref Google Scholar
[30]
L. Vecchione, M. Orditura, F. Ciardiello, and F. D. Vita, Novel investigational drugs for gastric cancer, Expert Opinion on Investigational Drugs, .
Crossref Google Scholar
[31]
R. Geng, L. Song, J. Li, and L. Zhao, The safety of apatinib for the treatment of gastric cancer, Expert Opin. Drug Saf., .
Crossref Google Scholar
[32]
D. A. Hescheler, P. S. Plum, T. Zander, A. Quaas, M. Korenkov, A. Gassa, M. Michel, C. J. Bruns, and H. Alakus, Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data, Gastric Cancer, .
Crossref Google Scholar
[33]
M. I. Love, W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., .
Crossref Google Scholar
[34]
P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, and T. Ideker, Cytoscape: A software environment for integrated models of biomolecular interaction networks, Genome Res., .
Crossref Google Scholar
[35]
D. W. Huang, B. T. Sherman, and R. A. Lempicki, Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res., .
Crossref Google Scholar
[36]
Z. Tang, B. Kang, C. Li, T. Chen, and Z. Zhang, GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis, Nucleic Acids Res., .
Crossref Google Scholar
[37]
M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L. Jenkins, K. M. Jagodnik, A. Lachmann, et al., Enrichr: A comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res., .
Crossref Google Scholar
[38]
J. Pinero, J. M. Ramírez-Anguita, J. Saüch-Pitarch, F. Ronzano, E. Centeno, F. Sanz, and L. I. Furlong, The DisGeNET knowledge platform for disease genomics: 2019 update, Nucleic Acids Res., .
Crossref Google Scholar
[39]
H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne, The protein data bank, Nucleic Acids Research, .
Crossref Google Scholar
[40]
A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F. T. Heer, T. A. P. D. Beer, C. Rempfer, L. Bordoli, et al., SWISS-MODEL: Homology modelling of protein structures and complexes, Nucleic Acids Res., .
Crossref Google Scholar
[41]
S. Kim, J. Chen, T. Cheng, A. Gindulyte, J. He, S. He, Q. Li, B. A. Shoemaker, P. A. Thiessen, B. Yu, et al., PubChem 2019 update: Improved access to chemical data, Nucleic Acids Res., .
Crossref Google Scholar
[42]
D. S. v4. 0. 100. 13345 Visualizer, Accelrys Software Inc, https://discover.3ds.com/discovery-studio-visualizer-download, 2005.
[43]
T. J. Dolinsky, P. Czodrowski, H. Li, J. E. Nielsen, J. H. Jensen, G. Klebe, and N. A. Baker, PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations, Nucleic Acids Res., .
Crossref Google Scholar
[44]
J. C. Gordon, J. B. Myers, T. Folta, V. Shoja, L. S. Heath, and A. Onufriev, H++: A server for estimating pKas and adding missing hydrogens to macromolecules, Nucleic Acids Res., .
Crossref Google Scholar
[45]
G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell, and A. J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem., vol. 30, no. 16, pp. 2785–2791, 2009.
Crossref Google Scholar
[46]
O. Trott and A. J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem., vol. 31, no. 2, pp. 455–461, 2010.
Crossref Google Scholar
[47]
W. L. Delano and S. Bromberg, PyMOL user’s guide, https://pymol.sourceforge.net/newman/userman.pdf, 2004.
[48]
W. L. DeLano, The PyMOL molecular graphics system, version 2.3, Schrödinger LLC, https://sourceforge.net/projects/pymol/, 2020.
[49]
D506-D515, UniProt: A worldwide hub of protein knowledge, The UniProt Consortium, Nucleic Acids Res., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323992/, 2019.
Google Scholar
[50]
O. M. Omar, M. Soutto, N. S. Bhat, A. A. Bhat, H. Lu, Z. Chen, and W. El-Rifai, TFF1 antagonizes TIMP-1 mediated proliferative functions in gastric cancer, Mol. Carcinog., vol. 57, no. 11, pp. 1577–1587, 2018.
Crossref Google Scholar
[51]
W. Chen and Z. Yang, Identification of differentially expressed genes reveals BGN predicting overall survival and tumor immune infiltration of gastric cancer, Comput. Math. Methods Med., .
Crossref Google Scholar
[52]
T. Chen, L. Sun, C. He, Y. Gong, Q. Xu, and Y. Yuan, Serum OPN expression for identification of gastric cancer and atrophic gastritis and its influencing factors, PLoS One, .
Crossref Google Scholar
[53]
D. Oikonomou, K. Hassan, J. T. Kaifi, H. C. Fiegel, P. G. Schurr, U. Reichelt, K. Aridome, E. F. Yekebas, O. Mann, D. Kluth, et al., Thy-1 as a potential novel diagnostic marker for gastrointestinal stromal tumors, J. Cancer Res. Clin. Oncol., vol. 133, no. 12, pp. 951–955, 2007.
Crossref Google Scholar
[54]
Y. C. Chuang, H. -Y. Wu, Y. -L. Lin, S. -C. Tzou, C. -H. Chuang, T. -Y. Jian, P. -R. Chen, Y. -C. Chang, C. -H. Lin, T. -H. Huang, et al., Blockade of ITGA2 induces apoptosis and inhibits cell migration in gastric cancer, Biol. Proced. Online, .
Crossref Google Scholar
[55]
S. Soleyman-Jahi, S. Nedjat, A. Abdirad, N. Hoorshad, R. Heidari, and K. Zendehdel, Prognostic significance of matrix metalloproteinase-7 in gastric cancer survival: A meta-analysis, PLoS One, .
Crossref Google Scholar
[56]
J. Qiu, M. Sun, Y. Wang, and B. Chen, Identification of hub genes and pathways in gastric adenocarcinoma based on bioinformatics analysis, Med. Sci. Monit., .
Crossref Google Scholar
[57]
B. Jiang, S. Li, Z. Jiang, and P. Shao, Gastric cancer associated genes identified by an integrative analysis of gene expression data, Biomed Res. Int., .
Crossref Google Scholar
[58]
X. Chong, R. Peng, Y. Sun, L. Zhang, and Z. Zhang, Identification of key genes in gastric cancer by bioinformatics analysis, Biomed Res. Int., .
Crossref Google Scholar
[59]
W. Wang, Y. He, Q. Zhao, X. Zhao, and Z. Li, Identification of potential key genes in gastric cancer using bioinformatics analysis, Biomed. Reports, vol. 12, no. 4, pp. 178–192, 2020.
Crossref Google Scholar
[60]
K. Hu and F. Chen, Identification of significant pathways in gastric cancer based on protein-protein interaction networks and cluster analysis, Genet. Mol. Biol., vol. 35, no. 3, pp. 701–708, 2012.
Crossref Google Scholar
[61]
D. Mao, R. Xu, H. Chen, X. Chen, D. Li, S. Song, Y. He, Z. Wei, and C. Zhang, Cross-talk of focal adhesion-related gene defines prognosis and the immune microenvironment in gastric cancer, Front. Cell Dev. Biol., .
Crossref Google Scholar
[62]
T. Matsuoka and M. Yashiro, The role of PI3K/Akt/mTOR signaling in gastric carcinoma, Cancers, vol. 6, no. 3, pp. 1441–1463, 2014.
Crossref Google Scholar
[63]
S. Luo, R. Lin, X. Liao, D. Li, and Y. Qin, Identification and verification of the molecular mechanisms and prognostic values of the cadherin gene family in gastric cancer, Sci. Rep., vol. 11, no. 1, p. 23674, 2021.
Crossref Google Scholar
[64]
R. Huang, W. Gu, B. Sun, and L. Gao, Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis, Mol. Med. Rep., vol. 17, no. 5, pp. 6387–6396, 2018.
Crossref Google Scholar
[65]
Y. L. Ding, S. F. Sun, and G. L. Zhao, COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis, Medicine (Baltimore)., vol. 100, no. 7, p. e24561, 2021.
Crossref Google Scholar
[66]
X. Liu and S. J. Meltzer, Gastric cancer in the era of precision medicine, CMGH, vol. 3, no. 3. pp. 348–358, 2017.
Crossref Google Scholar
[67]
G. A. Colditz, National cancer institute, SAGE Encycl. Cancer Soc., .
Crossref Google Scholar
[68]
T. Lim, J. Lee, D. J. Lee, H. Y. Lee, B. Han, K. K. Baek, H. K. Ahn, S. J. Lee, S. H. Park, J. O. Park, et al., Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer, Cancer Chemother. Pharmacol., vol. 68, no. 1, pp. 255–262, 2011.
Crossref Google Scholar
[69]
C. Pauligk, S. Janowski, K. Steinmetz, A. Atmaca, A. Pustowka, E. Jaeger, and S. Al-Batran, Daily RAD001 plus mitomycin C, every three weeks in previously treated patients with advanced gastric cancer or cancer of the esophagogastric junction: Preliminary results of a phase I study, J. Clin. Oncol., vol. 28, no. 15_suppl, p. e14531, 2010.
Crossref Google Scholar
[70]
T. Doi, K. Muro, N. Boku, Y. Yamada, T. Nishina, H. Takiuchi, Y. Komatsu, Y. Hamamoto, N. Ohno, and Y. Fujita, Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer, J. Clin. Oncol., vol. 28, no. 11, pp. 1904–1910, 2010.
Crossref Google Scholar
[71]
E. V. Cutsem, C. Boni, J. Tabernero, B. Massuti, G. Middleton, F. Dane, P. Reichardt, F. L. Pimentel, A. Cohn, P. Follana, et al., Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study, Ann. Oncol., vol. 26, no. 1, pp. 149–156, 2015.
Crossref Google Scholar
[72]
H. Lin, D. Han, G. Fu, C. Liu, L. Wang, S. Han, B. Liu, and J. Yu, Concurrent apatinib and docetaxel vs apatinib monotherapy as third-or subsequent-line therapy for advanced gastric adenocarcinoma: A retrospective study, Onco. Targets. Ther., vol. 12, pp. 1681–1689, 2019.
Crossref Google Scholar
[73]
E. M. Wolin, A. Manon, C. Chassaing, A. Lewis, L. Bertocchi, J. Richard, and A. T. Phan, Lanreotide depot: An antineoplastic treatment of carcinoid or neuroendocrine tumors, Journal of Gastrointestinal Cancer, vol. 47, no. 4. pp. 366–374, 2016.
Crossref Google Scholar
[74]
A. J. Souers, J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron, J. Chen, B. D. Dayton, H. Ding, S. H. Enschede, W. J. Fairbrother, et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat. Med., vol. 19, no. 2, pp. 202–208, 2013.
Crossref Google Scholar
[75]
H. Fukamachi, S. -K. Kim, J. Koh, H. S. Lee, Y. Sasaki, K. Yamashita, T. Nishikawaji, S. Shimada, Y. Akiyama, S. J. Byeon, et al., A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors, J. Exp. Clin. Cancer Res., .
Crossref Google Scholar
[76]
S. J. Byeon, N. Han, J. Choi, M. A. Kim, and W. H. Kim, Prognostic implication of TSC1 and mTOR expression in gastric carcinoma, J. Surg. Oncol., vol. 109, no. 8, pp. 812–817, 2014.
Crossref Google Scholar
[77]
S. E. Al-Batran, M. Ducreux, and A. Ohtsu, MTOR as a therapeutic target in patients with gastric cancer, International Journal of Cancer, vol. 130, no. 3. pp. 491–496, 2012.
Crossref Google Scholar
[78]
T. Murayama, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima, J. Kumagai, T. Kawano, and K. Sugihara, Relation between outcomes and localisation of p-mTOR expression in gastric cancer, Br. J. Cancer, vol. 100, no. 5, pp. 782–788, 2009.
Crossref Google Scholar
[79]
T. Huang, F. Zhou, X. Yuan, T. Yang, X. Liang, Y. Wang, H. Tu, J. Chang, K. Nan, and Y. Wei, Reactive oxygen species are involved in the development of gastric cancer and gastric cancer-related depression through ABL1-mediated inflammation signaling pathway, Oxid. Med. Cell. Longev., .
Crossref Google Scholar
[80]
N. Kassem, O. M. Ismail, H. Elomri, and M. A. Yassin, Nilotinib induced recurrent gastric polyps: Case report and review of literature, American Journal of Case Reports, vol. 18, pp. 794–798, 2017.
Crossref Google Scholar
Tsinghua Science and Technology
Volume 28 Issue 4,
August 2023
Pages 649-664
DOI: 10.26599/TST.2022.9010035
Cite this article:
Hossain MT, Reza MS, Peng Y, et al. Identification of Key Genes as Potential Drug Targets for Gastric Cancer. Tsinghua Science and Technology, 2023, 28(4): 649-664. https://doi.org/10.26599/TST.2022.9010035

1140

Views

153

Downloads

4

Crossref

3

Web of Science

4

Scopus

0

CSCD

Altmetrics
Received: 18 February 2022
Revised: 31 May 2022
Accepted: 29 August 2022
Published: 06 January 2023
© The author(s) 2023.

The articles published in this open access journal are distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
Return